Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


A Phase 0, Double-Blind, Randomized, Placebo-Controlled, Crossover Study to Assess Ketamine-induced Changes in ERP Biomarkers in Healthy Volunteers


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT04928703

Organisation Name: ERP Biomarker Qualification Consortium

Overal Status: Recruiting

Start Date: May 26, 2022

Last Update: June 6, 2022

Lead Sponsor: ERP Biomarker Qualification Consortium

Brief Summary: This is a Phase 0, Double-Blind, Randomized, Placebo-Controlled, Crossover Study to assess the changes in ERP Biomarkers in Healthy Volunteers before and after administration of a sub-anesthetic dose of ketamine. Primary objectives are to quantify the effect size of ketamine-induced changes on MMN from a duration-deviant auditory oddball ERP test and to quantify the variability of ketamine-induced changes on MMN from a duration-deviant auditory oddball ERP test.

Conditions:
  • Healthy


Total execution time in seconds: 0.52461004257202